DCM Advisors’s Corcept Therapeutics CORT Stock Holding History

DCM Advisors’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-15,000	Closed	-$385K	–	95
2022 Q3	$385K	Buy	+15,000	New	+$401K	0.19%	117

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DCM Advisors's CORT Position: Q4 2022 in Review

DCM Advisors sold out of Corcept Therapeutics (CORT) in Q4 2022, closing a stake of 15,000 shares — an estimated $385K sold.

DCM Advisors first reported a position in CORT in Q3 2022 and held it in 1 quarter. The position peaked at $385K in Q3 2022. 241 funds tracked by Wall St. Rank hold CORT as of Q4 2022.

DCM Advisors reported no remaining Corcept Therapeutics position as of Q4 2022 after selling out during the quarter.
DCM Advisors sold 15,000 Corcept Therapeutics shares in Q4 2022, an estimated $385K.
DCM Advisors first reported a position in Corcept Therapeutics in Q3 2022 and held it in 1 quarter.
DCM Advisors's Corcept Therapeutics position peaked at $385K in Q3 2022.
241 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2022.

Based on DCM Advisors's 13F filing for Q4 2022, filed 11 Sep 2023.